Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

NCT04984811 is registered in ClinicalTrials.gov with NeoImmuneTech as lead sponsor.

NCT NCT04984811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04984811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Lead sponsor
NeoImmuneTech
Phase
Phase 2
Overall status
Terminated
Start date
November 15, 2021
Completion date
September 19, 2024
Enrollment
33 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, non small cell lung cancer, non-small cell lung cancer, non-small cell lung carcinoma, nonsmall cell lung cancer